Gan and Lee Pharmaceuticals (SHSE:603087) Beta: 1.1424 (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603087 Gan and Lee Pharmaceuticals SHSE:603087
90 GF Score
Price ¥66.34
GF Value ¥73.00
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Gan and Lee Pharmaceuticals Beta?

Gan and Lee Pharmaceuticals SHSE:603087 -2.27% 90 Beta is 1.1424 as of Sep. 11, 2026. GuruFocus rates SHSE:603087 with a GF Score™ of 90/100 and a GF Value™ of ¥73.00 (Fairly Valued). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-09-11), Gan and Lee Pharmaceuticals's Beta is 1.1424.


Gan and Lee Pharmaceuticals  (SHSE:603087) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Gan and Lee Pharmaceuticals Beta Related Terms


Gan and Lee Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for Gan and Lee Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gan and Lee Pharmaceuticals Beta Chart

Gan and Lee Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1.45 1.46 1.66

Gan and Lee Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.33 1.37 1.66 1.54 1.49

SHSE:603087 vs ISRG, BDX, RMD: Beta Comparison

For the Medical Instruments & Supplies subindustry, Gan and Lee Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gan and Lee Pharmaceuticals Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gan and Lee Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Gan and Lee Pharmaceuticals's Beta falls into.


SHSE:603087
90GF Score
Gan and Lee Pharmaceuticals SHSE:603087
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gan and Lee Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.1424 mean?
Gan and Lee Pharmaceuticals (SHSE:603087) has a Beta of 1.1424 as of Sep. 11, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Gan and Lee Pharmaceuticals and its competitors.
Is Gan and Lee Pharmaceuticals' Beta too high?
Gan and Lee Pharmaceuticals' current Beta is 1.1424. Overall, Gan and Lee Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gan and Lee Pharmaceuticals' Beta compare to ISRG and BDX?
Gan and Lee Pharmaceuticals' Beta of 1.1424 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Gan and Lee Pharmaceuticals and its competitors. Gan and Lee Pharmaceuticals's current Beta is 1.1424. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gan and Lee Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals (SHSE:603087) is currently considered Fairly Valued. The stock's GF Value™ is ¥73.00, compared to a current price of ¥66.34 — trading 9.1% below its estimated fair value. The current Beta is 1.1424. Gan and Lee Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Gan and Lee Pharmaceuticals (SHSE:603087), the current Beta is 1.1424 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gan and Lee Pharmaceuticals (SHSE:603087) Overvalued in 2026?

Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued. The current stock price of ¥66.34 is trading 9.1% below its estimated GF Value™ of ¥73.00. GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.

Key valuation signals for SHSE:603087:

  • Beta: 1.1424
  • GF Value™: ¥73.00 vs. price of ¥66.34 (9.1% below fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gan and Lee Pharmaceuticals Business Description

Address No. 8, Nanfengxi 1st Road, Xianxian Town, Tongzhou District, Beijing, CHN, 101109
Gan and Lee Pharmaceuticals is engaged in Research, development, production and sales of recombinant insulin analog APIs and injections.
90GF Score

Get the complete analysis for SHSE:603087

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥66.34
Price
¥73.00
GF Value